Business Context and Reporting Period
This Form 8-K, filed on June 27, 2014, by Brookdale Senior Living Inc. (Brookdale), reports on events occurring on June 26, 2014. The filing serves as a supplemental disclosure to the joint proxy statement/prospectus regarding the proposed merger between Brookdale and Emeritus Corporation. The primary purpose is to disclose a proposed settlement of a shareholder class action lawsuit (In re Emeritus Corp. Shareholder Litigation) filed in Washington state challenging the merger.
Key Financial Metrics and Deal Terms
The filing does not report standard quarterly operating results (revenue, profit, cash flow) for Brookdale. Instead, it provides financial data related to the merger valuation and pro forma impacts:
- Merger Consideration: The settlement does not alter the consideration to be paid to Emeritus shareholders.
- Valuation Ranges (DCF Analysis):
- Wells Fargo Securities: Implied per share equity value range for Emeritus of $22.00 to $32.25; for Brookdale, $25.00 to $30.00.
- Moelis & Company: Implied per share reference range for Emeritus of approximately $26.05 to $36.99; for Brookdale, approximately $28.57 to $34.25.
- Pro Forma Accretion (CFFO per share): Based on a Brookdale closing price of $29.91 (Feb 19, 2014), the merger is estimated to be accretive to Emeritus standalone CFFO by 13.4% (2014) and 1.2% (2015), and accretive to Brookdale by 0.3% (2014) and 7.6% (2015).
- Estimated Synergies: Present value of expected synergies estimated between $386 million and $577 million.
- Debt Estimates (as of Dec 31, 2013):
- Emeritus: Long-term debt of $1.5 billion; capital lease/financial obligations of $2.5 billion.
- Brookdale: Long-term debt of $2.4 billion; line of credit of $30 million; current portion of long-term debt of $202 million.
Material Changes and Background Disclosures
The filing details the strategic process leading to the merger, including:
- Alternative Proposals: Emeritus explored various strategic options in 2013, including a real estate asset sale proposal from "Company A" and a transaction with "Company B" (offering 54% stock ownership plus a $6.25 cash dividend).
- Board Decision: The Emeritus Board rejected the Company A and Company B proposals in favor of the Brookdale transaction, citing better long-term value, more reliable synergy assumptions, and lower execution risks.
- Settlement Agreement: On June 26, 2014, the defendants entered a Memorandum of Understanding to settle the Washington shareholder lawsuit. This requires supplemental disclosures but does not admit wrongdoing.
- Timeline: Special shareholder meetings for both companies remain scheduled for July 10, 2014.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The settlement is intended to minimize the risk of litigation delaying the merger. Management believes the Brookdale transaction offers superior long-term value compared to alternatives. The filing includes extensive forward-looking statements regarding the merger's success and financial forecasts.
Risks and Contingencies:
- Settlement Approval: There is no assurance the court will approve the settlement or that the lawsuit will be dismissed.
- Merger Risks: Risks include failure to satisfy closing conditions, inability to obtain regulatory approvals, and failure to realize anticipated synergies.
- Operational Risks: General risks include changes in government reimbursement programs (Medicare/Medicaid), capital market liquidity, debt refinancing, and competition for senior housing assets.
- Financial Forecasts: Actual results may vary materially from the unaudited financial forecasts and synergy estimates provided.
Key Facts for Investor Verification
- Verify the final court approval status of the shareholder lawsuit settlement and its impact on the July 10, 2014 shareholder meeting.
- Review the full joint proxy statement/prospectus (Form S-4) for complete details on the merger terms and the "Company B" alternative offer.
- Confirm the accuracy of the unaudited debt figures ($1.5B for Emeritus, $2.4B for Brookdale) against the most recent audited financial statements.
- Assess the reliability of the synergy estimates ($386M-$577M) and the assumptions regarding Net Operating Loss (NOL) utilization.
- Monitor regulatory approval status for the merger, as delays could impact the transaction timeline.